Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 751.20 |
| Open | 764.49 |
| Bid | 782.90 x 1000 |
| Ask | 785.00 x 900 |
| Day's range | 758.63 - 789.95 |
| 52-week range | 538.01 - 789.95 |
| Volume | |
| Avg. volume | 651,804 |
| Market cap | 85.284B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 16.53 |
| EPS (TTM) | 47.38 |
| Earnings date | 02 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 812.75 |
- Zacks
Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Zacks
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline
Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.
- Zacks
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2023 Yahoo. All rights reserved.
